Neuropace Stock In The News
| NPCE Stock | USD 12.23 0.78 6.00% |
Our overall analysis of Neuropace's news coverage and content from conventional and social sources shows investors' bearish mood towards Neuropace. The specific impact of Neuropace news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Neuropace's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Neuropace headlines in addition to utilizing other, more conventional financial analysis modules. Check out Neuropace Backtesting and Neuropace Hype Analysis. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.
Neuropace |
Neuropace Today Top News and Investor Outlook
Neuropace Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Neuropace and other traded companies coverage with news coverage. We help investors stay connected with Neuropace headlines for the 7th of April to make an informed investment decision based on correlating the impacts of news items on Neuropace Stock performance. Please note that trading solely based on the Neuropace hype is not for everyone as timely availability and quick action are needed to avoid losses.
Neuropace stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Neuropace earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.
Neuropace Largest EPS Surprises
Earnings surprises can significantly impact Neuropace's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2021-11-10 | 2021-09-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2025-03-03 | 2024-12-31 | -0.2233 | -0.18 | 0.0433 | 19 | ||
2023-05-04 | 2023-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2024-11-12 | 2024-09-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2024-03-05 | 2023-12-31 | -0.31 | -0.23 | 0.08 | 25 |
Neuropace Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Neuropace Stock. Current markets are strongly bearish. About 89% of major world exchanges and indexes are down. See today's market update for more information.
3rd of April 2025
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval St... at globenewswire.com
2nd of April 2025
NeuroPace Announces Refocusing of Product Portfolio at gurufocus.com
26th of March 2025
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference at gurufocus.com
18th of March 2025
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India at news.google.com
10th of March 2025
Acquisition by Joel Becker of 99200 shares of Neuropace at 10.04 subject to Rule 16b-3 at news.google.com
7th of March 2025
Cantor Fitzgerald Predicts Higher Earnings for NeuroPace at thelincolnianonline.com
5th of March 2025
Q4 2024 Neuropace Inc Earnings Call Transcript at gurufocus.com
4th of March 2025
NeuroPace Inc. Q4 Earnings Snapshot at finance.yahoo.com
3rd of March 2025
NeuroPace to Present at the Leerink Partners Global Healthcare Conference at gurufocus.com
20th of February 2025
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. at gurufocus.com
29th of January 2025
Disposition of 100 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3 at news.google.com
Neuropace Investors Sentiment
The influence of Neuropace's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Neuropace. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Neuropace's public news can be used to forecast risks associated with an investment in Neuropace. The trend in average sentiment can be used to explain how an investor holding Neuropace can time the market purely based on public headlines and social activities around Neuropace. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuropace's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuropace's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Neuropace's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Neuropace.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuropace in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuropace's short interest history, or implied volatility extrapolated from Neuropace options trading.
Check out Neuropace Backtesting and Neuropace Hype Analysis. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.192 | Return On Assets | Return On Equity |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.